Pasar al contenido principal

IDENTIFICACION DE NUEVOS MECANISMOS DE ENVEJECIMIENTO Y ENFERMEDAD CARDIOVASCULAR REGULADOS POR LAMINAS TIPO A

PID2019-108489RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rolipram Prevents the Formation of Abdominal Aortic Aneurysm (AAA) in Mice: PDE4B as a Target in AAA

  • Varona, Saray
  • Puertas-Umbert, Lídia
  • Galán Arroyo, María
  • Orriols, Mar
  • Cañes, Laia
  • Aguiló, Silvia
  • Camacho, Mercedes
  • Sirvent, Marc
  • Andrés, Vicente
  • Martínez-González, José
  • Rodríguez-Sinovas, Cristina
Abdominal aortic aneurysm (AAA) is a common life-threatening condition characterized by exacerbated inflammation and the generation of reactive oxygen species. Pharmacological treatments to slow AAA progression or to prevent its rupture remain a challenge. Targeting phosphodiesterase 4 (PDE4) has been verified as an effective therapeutic strategy for an array of inflammatory conditions; however, no studies have assessed yet PDE4 in AAA. Here, we used angiotensin II (AngII)-infused apolipoprotein E deficient mice to study the involvement of the PDE4 subfamily in aneurysmal disease. PDE4B but not PDE4D was upregulated in inflammatory cells from both experimental and human AAA. The administration of the PDE4 selective inhibitor rolipram (3 mg/kg/day) to AngII-challenged mice (1000 ng/kg bodyweight/min) protected against AAA formation, limiting the progressive increase in the aortic diameter without affecting the blood pressure. The drug strongly attenuated the rise in vascular oxidative stress (superoxide anion) induced by AngII, and decreased the expression of inflammatory markers, as well as the recruitment of macrophages (MAC3+), lymphocytes (CD3+), and neutrophils (ELANE+) into the vessel wall. Rolipram also normalized the vascular MMP2 expression and MMP activity, preserving the elastin integrity and improving the vascular remodelling. These results point to PDE4B as a new therapeutic target for AAA., This work was supported by Instituto de Salud Carlos III (ISCIII) [PI18/0919], the Spanish Ministerio de Ciencia e Innovación (MICINN) [RTI2018-094727-B-100 and PID2019-108489RB-100], the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) [2017-SGR-00333], Sociedad Española de Arteriosclerosis [Beca FEA 2020 Investigación Básica], and Sociedad Española de Cardiología [SEC/FEC-INV-BAS 20/005]. The study was co-founded by Fondo Europeo de Desarrollo Regional (FEDER), “A way to make Europe”. L.C. was supported by a FI (AGAUR). The CNIC is supported by MICINN, ISCIII, and the Pro-CNIC Foundation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting Tyrosine Hydroxylase for Abdominal Aortic Aneurysm: Impact on Inflammation, Oxidative Stress, and Vascular Remodeling

  • Cañes, Laia
  • Alonso, Judith
  • Ballester-Servera, Carme
  • Varona, Saray
  • Escudero, José Román
  • Andrés, Vicente
  • Rodríguez-Sinovas, Cristina
  • Martínez-González, José
Pharmacological treatments for preventing abdominal aortic aneurysm (AAA) rupture or slowing aneurysm progression remain a challenge. It is increasingly recognized that sympathetic activity might play a role in the pathogenesis of AAA; however, the impact of this pathway remains unclear. Here, we show that the expression of tyrosine hydroxylase (TH), dopamine ß-hydroxylase (DBH), and the norepinephrine transporter SLC6A2 is upregulated in abdominal aorta samples from AAA patients and in the aneurysmal aorta from 2 animal models susceptible to Ang II (angiotensin II)¿induced AAA: the apolipoprotein E-deficient (ApoE¿/¿) model and a transgenic mouse that overexpresses the human nuclear receptor NOR-1 (neuron-derived orphan receptor-1) in the vascular wall (TgNOR-1VSMC). TH localizes to sympathetic nerves innervating the local vasculature, but also to inflammatory cells, and scattered vascular smooth muscle cell in human and mouse AAA. Interestingly, the preventive effect of doxycycline on AAA formation in Ang II¿treated TgNOR-1VSMC mice was associated to the normalization of vascular Th expression. Moreover, the TH specific inhibitor ¿-methyl-p-tyrosine protected against Ang II¿induced AAA formation, limiting the progressive increase in aortic diameter without affecting blood pressure. The drug normalized MMP2 (matrix metalloproteinase 2) expression and MMP activity, preserving elastin integrity, attenuated the Ang II¿mediated rise in vascular oxidative stress and inflammatory markers and reduced the inflammatory infiltrate. Finally, NOR-1, whose expression correlated with that of TH in human AAA, was able to drive human TH transcriptional activity in transient transfection assays. Therefore, the upregulation of the TH pathway could be critical in the pathophysiology of AAA, supporting the potential of pharmacological strategies targeting TH for AAA management., This work was supported by the Spanish Ministerio de Ciencia e Innovación (RTI2018-094727-B-100 and PID2019-108489RB-100), Instituto de Salud Carlos III (ISCIII; PI18/0919), the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR; 2017-SGR-00333), and Sociedad Española de Arteriosclerosis (SEA-2019). The study was cofounded by Fondo Europeo de Desarrollo Regional (FEDER), a way to make Europe. L. Cañes and C. Ballester-Servera were supported by a FI (AGAUR) and a FPU fellowship (Ministerio de Universidades), respectively., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Coronary and carotid artery dysfunction and KV7 overexpression in a mouse model of Hutchinson-Gilford progeria syndrome

  • Macías, Álvaro
  • Nevado, Rosa M.
  • González-Gómez, Cristina
  • Gonzalo, Pilar
  • Andrés-Manzano, María J.
  • Dorado, Beatriz
  • Benedicto, Ignacio
  • Andrés, Vicente
18 p.-6 fig.-1 tab., Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare genetic disease caused by expression of progerin, a lamin A variant that is also expressed at low levels in non-HGPS individuals. Although HGPS patients die predominantly from myocardial infarction and stroke, the mechanisms that provoke pathological alterations in the coronary and cerebral arteries in HGPS remain ill defined. Here, we assessed vascular function in the coronary arteries (CorAs) and carotid arteries (CarAs) of progerin-expressing LmnaG609G/G609G mice (G609G), both in resting conditions and after hypoxic stimulus. Wire myography, pharmacological screening, and gene expression studies demonstrated vascular atony and stenosis, as well as other functional alterations in progeroid CorAs and CarAs and aorta. These defects were associated with loss of vascular smooth muscle cells and overexpression of the KV7 family of voltage-dependent potassium channels. Compared with wild-type controls, G609G mice showed reduced median survival upon chronic isoproterenol exposure, a baseline state of chronic cardiac hypoxia characterized by overexpression of hypoxia-inducible factor 1α and 3α genes, and increased cardiac vascularization. Our results shed light on the mechanisms underlying progerin-induced coronary and carotid artery disease and identify KV7 channels as a candidate target for the treatment of HGPS., Work supported by Ministerio de Ciencia e Innovación (MCIN) and Agencia Estatal de Investigación (AEI) (MCIN/AEI/https://doi.org/10.13039/501100011033 grants SAF2016-79490-R and PID2019-108489RB-I00), with co-funding from Fondo Social Europeo (“El FSE invierte en tu futuro”), and a donation from Asociación Progeria Alexandra Peraut. Microscopy was conducted at the Microscopy & Dynamic Imaging Unit, CNIC, ICTS-ReDib, co-funded by MCIN/AEI/https://doi.org/10.13039/501100011033. R.M.N was supported by the Ministerio de Educación, Cultura y Deporte (pre-doctoral contract FPU16/05027), and I.B. is supported by the Comunidad Autónoma de Madrid (grants 2017-T1/BMD-5247 and 2021-5A/BMD-20944), and the Ramón y Cajal contract (RYC2021-033805-I) funded by MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR. The CNIC is supported by the MCIN, the Instituto de Salud Carlos III, the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant number CEX2020-001041-S funded by MCIN/AEI/https://doi.org/10.13039/501100011033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Progerin expression in endothelial cells is not a causal driver of cardiovascular alterations and premature death in progeria

  • Benedicto, Ignacio
  • Carmona, Rosa María
  • Barettino, Ana
  • Espinós-Estévez, Carla
  • Gonzalo, Pilar
  • Nevado, Rosa M.
  • Andrés-Manzano, María J.
  • González-Gómez, Cristina
  • Dorado, Beatriz
  • Hamczyk, Magda R.
  • Andrés, Vicente
1 p.-9 fig., The most clinically relevant feature of Hutchinson-Gilford progeria syndrome (HGPS) is the development of severe cardiovascular alterations, including massive loss of vascular smooth muscle cells, vessel stiffening, vascular calcification and fibrosis, and generalized atherosclerosis, as well as electrical,structural, and functional anomalies in the heart. As a result, most HGPS patients die of myocardial infarction, heart failure, or stroke in their mid-teens.Here, we tested whether progerin expression in endothelial cells (ECs) has a direct causal role in HGPS. To tackle this issue, we generated mouse models with endothelium-specific progerin expression (LCS iEC) and suppression (HGPSrev iEC), the latter together with lamin A restoration., Work in V.A.’s laboratory is supported by grants from the Spanish Ministerio de Ciencia e Innovación (MCIN)/Agencia Estatal de Investigación (AEI)/10.13039/501100011033; grant PID2019-108489RB-I00 and Instituto de Salud Carlos III (ISCIII) (grant AC22/00020),with co-funding from the European Social Fund (“The ESF invests in your future”) and by the “European Union NextGenerationEU/PRTR”, Fundación Ramón Areces, the Progeria Research Foundation (grant PRF2019–77), Asociación Progeria Alexandra Peraut, Fundació Marató TV3 (grant 202033-31), and Sociedad Española de Cardiología (SEC/FEC-INV-BAS 22/005). Microscopy was conducted at the Microscopy & Dynamic Imaging Unit, CNIC, ICTS-ReDib, co-funded by MCIN/AEI /10.13039/501100011033. I.B. is supported by the Comunidad de Madrid (grants 2017- T1/BMD-5247 and 2021-5A/BMD-20944) and a Ramón y Cajal contract (RYC2021-033805-I) funded by MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR. A.B. was supported by MCIN (predoctoral contract BES-2017-079705) and C.E.-E. by Fundación "la Caixa” (grant LCF/BQ/DR19/1170012). The CNIC is supported by the ISCIII, the MCIN, and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MCIN/AEI/10.13039/501100011033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Endothelial YAP/TAZ activation promotes atherosclerosis in a mouse model of Hutchinson-Gilford progeria syndrome

  • Barettino, Ana
  • González-Gómez, Cristina
  • Gonzalo, Pilar
  • Andrés-Manzano, María J.
  • Guerrero, Carlos R.
  • Espinosa, Francisco M.
  • Carmona, Rosa María
  • Blanco, Yaazan
  • Dorado, Beatriz
  • Torroja, Carlos
  • Sánchez-Cabo, Fátima
  • Quintas, Ana
  • Benguría, Alberto
  • Dopazo, Ana
  • García, Ricardo
  • Benedicto, Ignacio
  • Andrés, Vicente
17 p.-8 fig.-1 graph. abst., Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare disease caused by the expression of progerin, an aberrant protein produced by a point mutation in the LMNA gene. HGPS patients show accelerated aging and die prematurely mainly from complications of atherosclerosis such as myocardial infarction, heart failure, or stroke. However, the mechanisms underlying HGPS vascular pathology remain ill defined. We used single-cell RNA sequencing to characterize the aorta in progerin-expressing LmnaG609G/G609G mice and wild-type controls, with a special focus on endothelial cells (ECs). HGPS ECs showed gene expression changes associated with extracellular matrix alterations, increased leukocyte extravasation, and activation of the yes-associated protein 1/transcriptional activator with PDZ-binding domain (YAP/TAZ) mechanosensing pathway, all validated by different techniques. Atomic force microscopy experiments demonstrated stiffer subendothelial extracellular matrix in progeroid aortas, and ultrasound assessment of live HGPS mice revealed disturbed aortic blood flow, both key inducers of the YAP/TAZ pathway in ECs. YAP/TAZ inhibition with verteporfin reduced leukocyte accumulation in the aortic intimal layer and decreased atherosclerosis burden in progeroid mice. Our findings identify endothelial YAP/TAZ signaling as a key mechanism of HGPS vascular disease and open a new avenue for the development of YAP/TAZ targeting drugs to ameliorate progerin-induced atherosclerosis., This study was supported by grants to V.A. from the Spanish Ministerio de Ciencia,Innovación y Universidades (MICIU) and Agencia Estatal de Investigación (AEI) (MICIU/AEI/10.13039/501100011033 grant PID2019-108489RB-I00), with cofunding from Fondo Social Europeo (FSE) (“El FSE invierte en tu futuro”), and a donation from Asociación Progeria Alexandra Peraut. I.B. was supported by Comunidad Autónoma de Madrid (grants 2017-T1/BMD-5247 and 2021-5A/BMD-20944) with co-funding from the European Structural and Investment Fund, a Ramón y Cajal contract (RYC2021-033805-I) funded by MICIU AEI/10.13039/501100011033 and European Union “NextGenerationEU”/PRTR, and grant PID2022-137111OA-I00 (MICIU/AEI/10.13039/501100011033, ERDF/EU). A. Barettino was supported by predoctoral contract BES-2017-079705 (MICIU/AEI/10.13039/501100011033 and FSE “El FSE invierte en tu futuro”). R.G. was supported by grants PID2019-106801GB-I00/AEI/10.13039/501100011033 and S2018/NMT-4443 (Tec4Bio-CM).The Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) is supported by the MICIU, the Instituto de Salud Carlos III, the Pro-CNIC Foundation,and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033)., Peer reviewed